Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

ROS1 copy number alterations are frequent in non-small cell lung cancer.

Clavé S, Gimeno J, Muñoz-Mármol AM, Vidal J, Reguart N, Carcereny E, Pijuan L, Menéndez S, Taus Á, Mate JL, Serrano S, Albanell J, Espinet B, Arriola E, Salido M.

Oncotarget. 2016 Feb 16;7(7):8019-28. doi: 10.18632/oncotarget.6921.

2.

Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.

Go H, Kim DW, Kim D, Keam B, Kim TM, Lee SH, Heo DS, Bang YJ, Chung DH.

J Thorac Oncol. 2013 Nov;8(11):1445-50. doi: 10.1097/JTO.0b013e3182a4dd6e.

3.

Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.

Kim H, Yoo SB, Choe JY, Paik JH, Xu X, Nitta H, Zhang W, Grogan TM, Lee CT, Jheon S, Chung JH.

J Thorac Oncol. 2011 Aug;6(8):1359-66. doi: 10.1097/JTO.0b013e31821cfc73.

4.

On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.

Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, Audigier-Valette C, Sabourin JC, Decroisette C, Sakhri L, Brambilla E, McLeer-Florin A.

Lung Cancer. 2014 Feb;83(2):168-73. doi: 10.1016/j.lungcan.2013.11.019. Epub 2013 Dec 1.

PMID:
24380695
5.

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.

Pailler E, Auger N, Lindsay CR, Vielh P, Islas-Morris-Hernandez A, Borget I, Ngo-Camus M, Planchard D, Soria JC, Besse B, Farace F.

Ann Oncol. 2015 Jul;26(7):1408-15. doi: 10.1093/annonc/mdv165. Epub 2015 Apr 6.

6.

ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.

Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada Y, Asamura H, Furuta K, Shibata T, Tsuda H.

Am J Surg Pathol. 2013 Apr;37(4):554-62. doi: 10.1097/PAS.0b013e3182758fe6.

PMID:
23426121
7.

Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.

Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, Lee JS, Jheon S, Chung JH.

J Thorac Oncol. 2011 Mar;6(3):466-72. doi: 10.1097/JTO.0b013e31820b82e8.

8.

Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.

Tran TN, Selinger CI, Kohonen-Corish MR, McCaughan B, Kennedy C, O'Toole SA, Cooper WA.

Clin Lung Cancer. 2016 Jan;17(1):30-8.e1. doi: 10.1016/j.cllc.2015.08.002. Epub 2015 Aug 18.

PMID:
26395411
9.
10.

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.

Wiesweg M, Eberhardt WEE, Reis H, Ting S, Savvidou N, Skiba C, Herold T, Christoph DC, Meiler J, Worm K, Kasper S, Theegarten D, Hense J, Hager T, Darwiche K, Oezkan F, Aigner C, Welter S, Kühl H, Stuschke M, Schmid KW, Schuler M.

J Thorac Oncol. 2017 Jan;12(1):54-64. doi: 10.1016/j.jtho.2016.08.137. Epub 2016 Aug 27.

11.

Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.

Jurmeister P, Lenze D, Berg E, Mende S, Schäper F, Kellner U, Herbst H, Sers C, Budczies J, Dietel M, Hummel M, von Laffert M.

Lung Cancer. 2015 Feb;87(2):122-9. doi: 10.1016/j.lungcan.2014.11.018. Epub 2014 Dec 6.

PMID:
25534130
12.

Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.

Selinger CI, Li BT, Pavlakis N, Links M, Gill AJ, Lee A, Clarke S, Tran TN, Lum T, Yip PY, Horvath L, Yu B, Kohonen-Corish MR, O'Toole SA, Cooper WA.

Histopathology. 2017 Feb;70(3):402-411. doi: 10.1111/his.13076. Epub 2016 Nov 15.

13.

Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.

Lim SM, Chang H, Cha YJ, Liang S, Tai YC, Li G, Pestova E, Policht F, Perez T, Soo RA, Park WY, Kim HR, Shim HS, Cho BC.

Lung Cancer. 2017 Sep;111:79-83. doi: 10.1016/j.lungcan.2017.07.016. Epub 2017 Jul 12.

PMID:
28838404
14.

ROS1 rearrangements define a unique molecular class of lung cancers.

Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ.

J Clin Oncol. 2012 Mar 10;30(8):863-70. doi: 10.1200/JCO.2011.35.6345. Epub 2012 Jan 3.

15.

Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.

Cabillic F, Gros A, Dugay F, Begueret H, Mesturoux L, Chiforeanu DC, Dufrenot L, Jauffret V, Dachary D, Corre R, Lespagnol A, Soler G, Dagher J, Catros V, Le Calve M, Merlio JP, Belaud-Rotureau MA.

J Thorac Oncol. 2014 Mar;9(3):295-306. doi: 10.1097/JTO.0000000000000072.

16.

Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.

Al-Saad S, Al-Shibli K, Donnem T, Andersen S, Bremnes RM, Busund LT.

J Thorac Oncol. 2010 Oct;5(10):1536-43. doi: 10.1097/JTO.0b013e3181ea510a.

17.

ROS1 gene rearrangement and copy number gain in non-small cell lung cancer.

Jin Y, Sun PL, Kim H, Park E, Shim HS, Jheon S, Kim K, Lee CT, Chung JH.

Virchows Arch. 2015 Jan;466(1):45-52. doi: 10.1007/s00428-014-1679-2. Epub 2014 Nov 6. Erratum in: Virchows Arch. 2015 Jul;467(1):123.

PMID:
25374304
18.

[Detection of ROS1 gene rearrangement by FISH and analysis of its clinical features in non-small cell lung cancer patients].

Cheng H, Ye L, Xue L.

Zhonghua Zhong Liu Za Zhi. 2014 Oct;36(10):751-4. Chinese.

PMID:
25567305
19.

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.

Sholl LM, Sun H, Butaney M, Zhang C, Lee C, Jänne PA, Rodig SJ.

Am J Surg Pathol. 2013 Sep;37(9):1441-9. doi: 10.1097/PAS.0b013e3182960fa7.

20.

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.

Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS, Kang DR, Soo RA, Haack H, Kim JH, Shim HS, Cho BC.

Ann Oncol. 2013 Sep;24(9):2364-70. doi: 10.1093/annonc/mdt220. Epub 2013 Jun 19.

PMID:
23788756

Supplemental Content

Support Center